Elite Pharmaceuticals, Inc.
ELTP
$0.26
$0.00-1.08%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -67.98% | -0.71% | 35.70% | 332.85% | -134.62% |
| Total Depreciation and Amortization | 0.18% | -2.98% | -0.76% | 0.55% | -2.34% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 115.46% | 30.31% | -93.36% | -119.28% | 746.04% |
| Change in Net Operating Assets | 194.06% | 80.80% | -268.62% | 45.72% | 24.25% |
| Cash from Operations | 10.10% | 273.28% | -203.41% | -65.46% | 277.13% |
| Capital Expenditure | -103.27% | -93.11% | -99.52% | 52.66% | 71.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -103.27% | -93.11% | -99.52% | 52.66% | 71.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 1.25% | 2.99% | 53.55% | 93.55% | -2,542.80% |
| Issuance of Common Stock | -94.90% | -12.97% | -39.87% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -176.14% | -23.51% | 71.16% | 97.18% | -2,915.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.05% | 257.79% | -212.97% | -53.16% | 244.48% |